Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
ACTG has launched A5374, a Phase I/IIa clinical trial to evaluate the safety, tolerability, and antiviral effect of a ...
head of the HIV Prevention Trials Network says there are four areas of research which are being investigated in HIV; ...
Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...
EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...
Treatment for HIV/AIDS has consistently seen progress each ... The results of the iPrEx study were released in 2010, finding that a daily dose of HIV drugs reduced the risk of HIV infection ...
A study of nearly 1,000 gay male couples in The Lancet found no cases of HIV transmission over eight years. This was due to treatment reducing the virus to very low levels in the body.
[2] Measures of effectiveness include pregnancy rate per treatment cycle, cumulative clinical pregnancy rate (CCPR) and cumulative live-birth rate (CLBR), while rates of HIV seroconversion and ...
Blog - allAfrica's Sethi Ncube is in Lima, Peru, for the 5th HIV Research for Prevention Conference, HIVR4P 2024, reporting ...
The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...